EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of O-Glycosylation and N-Glycosylation in Bispecific Antibodies and Its Importance in Therapeutic Antibody Development

Maoqin Duan iD, Luyun Guo, Zhen Long, Yongbo Ni, Yalan Yang, Jialiang Du iD, Meng Li, Jialing Zhang, Tao Tang, Chuanfei Yu, Lan Wang

Pharmaceuticals · 13.10.2025 · 18 (10) · 1538

DOI: 10.3390/ph18101538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 13.10.2025. Verfasst von Maoqin Duan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech, Division of Monoclonal Antibody Products, National I…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Key Laboratory of Drug Regulatory Science Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: This study comprehensively characterized the O- and N-glycosylation profiles of bispecific antibodies (BsAbs) via advanced analytical techniques to evaluate their structural and functional implications.

Methods

High-resolution MS revealed O-xylosylation at Ser468 within the (G4S)4 linker peptide, which was identified as xylose with a molecular weight of 132.042 Da. HILIC-HPLC analysis of N-glycosylation revealed glycan species engineered to eliminate Fc effector functions. O-glycosylation analysis via β-elimination followed by high-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD) identified xylose as the predominant glycan.

Results

O-xylosylation does not affect the binding of BsAbs to either antigen Programmed Death-1 (PD-1) or Vascular Endothelial Growth Factor (VEGF). Notably, O-xylosylation interactions with mannose receptor represent the first discovery highlighting potential immunomodulatory roles.

Conclusions

This study highlights the critical importance of monitoring comprehensive glycosylation characterization during the development of BsAb with (G4S)n linkers to ensure optimal therapeutic efficacy, safety, and reduced immunogenic potential.

Schlagwörter

Stichwörter der Autor:innen

BsAbsELISAHILIC-HPLCHPAEC-PADMSN-glycosylationO-glycosylationmannose receptor

Autor:innen und Institutionen

  • Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech, Division of Monoclonal Antibody Products, National Institutes for Food and Drug Control, Beijing 102629, China.
  • ThermoFisher Scientific Corporation, Beijing 100080, China.

ORCID-Profile: Maoqin Duan, Jialiang Du

Förderung

  • State Key Laboratory of Drug Regulatory Science Project

Zitieren

APA

Duan, M., Guo, L., Long, Z., Ni, Y., Yang, Y., Du, J., Li, M., Zhang, J., Tang, T., Yu, C., & Wang, L. (2025). Characterization of O-Glycosylation and N-Glycosylation in Bispecific Antibodies and Its Importance in Therapeutic Antibody Development. Pharmaceuticals, 18(10), 1538. https://doi.org/10.3390/ph18101538

Vancouver

Duan M, Guo L, Long Z, Ni Y, Yang Y, Du J, et al. Characterization of O-Glycosylation and N-Glycosylation in Bispecific Antibodies and Its Importance in Therapeutic Antibody Development. Pharmaceuticals. 2025;18(10):1538. doi:10.3390/ph18101538

BibTeX
@article{Duan2025,
  author = {Duan, Maoqin and Guo, Luyun and Long, Zhen and Ni, Yongbo and Yang, Yalan and Du, Jialiang and Li, Meng and Zhang, Jialing and Tang, Tao and Yu, Chuanfei and Wang, Lan},
  title = {Characterization of O-Glycosylation and N-Glycosylation in Bispecific Antibodies and Its Importance in Therapeutic Antibody Development},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {10},
  pages = {1538},
  doi = {10.3390/ph18101538}
}
Kostenlos starten →